Search
Afamelanotide
go.drugbank.com/drugs/DB04931ApprovedAfamelanotide is a first-in-class, synthetic, 13-amino acid peptide analogue of the endogenous alpha melanocyte-stimulating hormone (α-MSH). … [L9092] Despite its relatively recent approval, afamelanotide has been available for use as an orphan drug in both the US and EU since 2008.[L9122,L9125]
Categories: Melanocortin 1 Receptor (MC1-R) Agonists, Compounds used in a research, industrial, or household settingSynonyms: MT-I, Melanotan 1Eritoran
go.drugbank.com/drugs/DB04933InvestigationalEritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.
Categories: Toll-Like Receptor 4, antagonists & inhibitorsAzimilide
go.drugbank.com/drugs/DB04957InvestigationalIt is not approved for use in any country, but is currently in clinical trials in the United States. … Azimilide is an investigational class III anti-arrhythmic drug that blocks fast and slow components of the delayed rectifier cardiac potassium channels.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 1-((5-(P-CHLOROPHENYL)FURFURYLIDENE)AMINO)-3-(4-(4-METHYL-1-PIPERAZINYL)BUTYL)HYDANTOIN, 2,4-IMIDAZOLIDINEDIONE, 1-(((5-(4-CHLOROPHENYL)-2-FURANYL)METHYLENE)AMINO)-3-(4-(4-METHYL-1-PIPERAZINYL)BUTYL)-Denufosol
go.drugbank.com/drugs/DB04983InvestigationalA new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol. … Denufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial.
Categories: Heterocyclic Compounds, 1-RingMigalastat
go.drugbank.com/drugs/DB05018ApprovedInvestigationalFabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A). … [L47036,L47057,L4274,L4278] In these patients, migalastat works by stabilizing the body’s dysfunctional alpha-Gal A enzyme so that it can clear the accumulation of glycosphingolipid disease substrate.
Categories: Alpha-Galactosidase A (alpha-Gal A) Pharmacological Chaperones, Heterocyclic Compounds, 1-RingSynonyms: (2R,3S,4R,5S)-2-(Hydroxymethyl)piperidine-3,4,5-triol, 1-DeoxygalactostatinElafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigationalElafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist [A263833] that works to inhibit bile acid synthesis.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersSynonyms: PROPANOIC ACID, 2-(2,6-DIMETHYL-4-((1E)-3-(4-(METHYLTHIO)PHENYL)-3-OXO-1-PROPEN-1-YL)PHENOXY)-, PROPANOIC ACID, 2-(2,6-DIMETHYL-4-(3-(4-(METHYLTHIO)PHENYL)-3-OXO-1-PROPEN-1-YL)PHENOXY)-2-METHYL-Beraprost
go.drugbank.com/drugs/DB05229InvestigationalBeraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.
Categories: Prostaglandins I, Cytochrome P-450 SubstratesProducts: ดอร์เนอ(R) ชนิดเม็ด 20 ไมโครกรัมRotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalIt is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours. … Rotigotine has been authorized as a treatment for RLS since August 2008.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: (6S)-6-(propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenolHistamine
go.drugbank.com/drugs/DB05381ApprovedInvestigationalIt is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. … A depressor amine derived by enzymatic decarboxylation of histidine.
Mixtures: Histamine DHCl 0.10 Percent and Menthol 2 PercentCategories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 CYP3A InhibitorsCanertinib
go.drugbank.com/drugs/DB05424InvestigationalCanertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. … Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.
Categories: Heterocyclic Compounds, 1-Ring, Compounds used in a research, industrial, or household setting